GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST.

A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead

Read More

EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug …

WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it will host a key opinion leader roundtable discussion on the future of local drug delivery for wet aged-related macular degeneration (AMD) and an overview of EYP-1901, the Company’s potential six-month sustained delivery intravitreal anti-VEGF therapy for wet AMD. The event will take place virtually on Friday, December 4, 2020, at 12:00 p.m. ET.

Scheduled to participate in the event are several leading retina specialists, including Robert Avery, M.D., Founder and Chief Executive Officer, California Retina Consultants; Elias Reichel, M.D., Professor and Vice Chair, Director, Vitreoretinal Service, New England Eye Center, Tufts University of Medicine; and Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Houston, Deputy Chair For Ophthalmology, Blanton Eye Institute.

To access the event, please dial (877) 870-4263 from the

Read More

Why Zomedica Pharmaceuticals Is Surging Today



a dog wearing a bow tie: A close-up shot of a smiling veterinarian and a grey fluffy dog.


© Source: Shutterstock
A close-up shot of a smiling veterinarian and a grey fluffy dog.

Animal lovers, unite! Zomedica Pharmaceuticals (NYSEMKT:ZOM), an under-the-radar play on the pet care space, is having an impressive time in the stock market today. In fact, one big catalyst has ZOM stock up more than 20% today.



a dog wearing a collar shirt: A close-up shot of a smiling veterinarian and a grey fluffy dog.


© Provided by InvestorPlace
A close-up shot of a smiling veterinarian and a grey fluffy dog.

So what exactly is Zomedica Pharmaceuticals? And what is that big catalyst? Starting with the first question, Zomedica Pharmaceuticals says that its goal is to improve the quality of veterinarian care by helping more veterinarians be successful. To do this, Zomedica works to provide veterinarian solutions that help with diagnostics.

Essentially, the easier it is for vets to figure out what is wrong with an animal, the easier it is to begin treatment.

Loading...

Load Error

With that in mind, Zomedica

Read More

Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results

– Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –

WEST CHESTER, Penn., Nov. 09, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020.

“We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear alignment on the path forward to resubmit the NDA, which we anticipate in the first quarter of 2021. In addition,

Read More

3 Red Flags for Inovio Pharmaceuticals’ Future

In the early days of the coronavirus pandemic, Inovio Pharmaceuticals (NASDAQ:INO) was an exciting frontrunner in the vaccine race. The company garnered attention after it claimed to have created its candidate, DNA vaccine INO-4800, within three hours of receiving the genetic sequence of SARS-CoV-2 from a team of Chinese researchers. Fast-forward 10 months, and it’s clear that Inovio significantly lags behind peers such as Moderna, Pfizer, and AstraZeneca, who already have phase 3 clinical trials underway.

Indeed, Inovio stock is now down nearly 70% from its peak as investors are arguably dismayed over the pace of Inovio’s vaccine development. However, more concerning factors behind the company’s rapid fall from grace still linger, and they point to a bleak future. Today let’s take a look at why investors should be in no hurry to buy Inovio’s stock on the dip.

Vials with the words covid-19 vaccine on them

Image source: Getty Images.

1. The lack of

Read More

Pharmather Secures Exclusive Rights to Novel Microneedle Delivery Technology for Psychedelic Pharmaceuticals

Figure 1

Actual GelMA-MN patch (10x close up)
Actual GelMA-MN patch (10x close up)
Actual GelMA-MN patch (10x close up)

TORONTO, Oct. 22, 2020 (GLOBE NEWSWIRE) — Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle (“GelMA-MN”) delivery technology developed at the University of California, Los Angeles (“UCLA”) for use with psychedelic pharmaceuticals, including, but not limited to Psilocybin, Ketamine, Ibogaine, LSD, MDMA, DMT, and Cannabinoids.

“We are very pleased to have acquired the rights to this novel microneedle delivery technology as it strengthens the foundation of our strategy to develop and commercialize a unique pipeline of psychedelic

Read More